ABT450
- CAS No.
- 1216941-48-8
- Chemical Name:
- ABT450
- Synonyms
- ATB450;ABT450 5MG;Paritaprevir;Paritaprevir D4;ABT450/Paritaprevir;Paritaprevir(ABT-450);ABT-450;ABT450;ABT 450;Papaverine Impurity 14;Paritaprevir, 10 mM in DMSO;Paritaprevir(Veruprevir ABT-450)
- CBNumber:
- CB22748429
- Molecular Formula:
- C40H43N7O7S
- Molecular Weight:
- 765.88
- MDL Number:
- MFCD28411394
- MOL File:
- 1216941-48-8.mol
| Density | 1.45±0.1 g/cm3(Predicted) |
|---|---|
| storage temp. | 4°C, away from moisture and light |
| solubility | DMSO:30.0(Max Conc. mg/mL);39.2(Max Conc. mM) |
| form | A solid |
| pka | 4.41±0.60(Predicted) |
| color | White to off-white |
| FDA UNII | OU2YM37K86 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H315-H319-H335 | |||||||||
| Precautionary statements | P261-P264-P270-P271-P280-P301+P312-P330-P302+P352-P321-P304+P340-P305+P351+P338-P332+P313-P362+P364-P337+P313-P403+P233-P405-P501 | |||||||||
| NFPA 704 |
|
ABT450 price More Price(14)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 28301 | Paritaprevir | 1216941-48-8 | 10mg | $272 | 2024-03-01 | Buy |
| Cayman Chemical | 28301 | Paritaprevir | 1216941-48-8 | 25mg | $549 | 2024-03-01 | Buy |
| Cayman Chemical | 28301 | Paritaprevir | 1216941-48-8 | 5mg | $171 | 2024-03-01 | Buy |
| TRC | P195305 | Paritaprevir | 1216941-48-8 | 50mg | $31350 | 2021-12-16 | Buy |
| American Custom Chemicals Corporation | API0026049 | ABT-450 95.00% | 1216941-48-8 | 5MG | $504.59 | 2021-12-16 | Buy |
ABT450 Chemical Properties,Uses,Production
Description
Paritaprevir hydrate, a second-generation NS3/4A protease inhibitor, is a component of the all-oral, interferon-free hepatitis C virus combination therapy developed by Enanta Pharmaceuticals and AbbVie. The fixed-dose tablet of paritaprevir, ombitasvir (XXV, NS4A replication complex inhibitor), and ritonavir (cytochrome P450 inhibitor) taken in combination with dasabuvir (X, NS5B polymerase inhibitor) was approved for the treatment of chronic HCV genotype 1 in the USA and EU in 2014, and further approved for treatment of genotype 4 chronic HCV infection without cirrhosis by the US FDA in 2015. After 12 weeks of combination treatment, high sustained virological response rates have been demonstrated in clinical trials.205 Paritaprevir joins other marketed NS3/4A inhibitors, including telaprevir, boceprevir, simeprevir, and vaniprevir (XXXVIII), which inhibit a critical enzymatic complex for HCV replication. It exhibits potent antiviral activity against HCV genotype 1a and 1b strains, with EC50 values of 1.0 and 0.21 nM respectively. As paritaprevir is metabolized by CYP3A4, ritonavir, a CYP3A inhibitor with no direct HCV antiviral properties, is dosed concurrently to boost paritaprevir exposure, raising the mean plasma half-life to ca. 5.5 h and allowing for once-daily dosing. While several development routes for paritaprevir have been published in the patent literature, no process route has been disclosed to date. Perceptibly the most scalable route is described below; no yields for this route have been reported. Notably, the synthesis of a closely related compound that shares the same macrocylic core has been reported by AbbVie on kilogram scale.
Uses
Paritaprevir is a pharmaceutical drug that is used in the treatment of hepatitis C virus in patients with HCV genotype 1 infection. It inhibits an important viral phosphoprotein, NS5A, which is involved in viral replication, assembly, and secretion.
Definition
ChEBI: An azamacrocycle which is used which is in combination with dasabuvir sodium hydrate, ombitasvir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.
Synthesis
Commercial (2S,4R)-N-Boc-4-hydroxyproline (219)
was reacted with 6-chlorophenanthridine (220) in NMP in the
presence of sodium t-butoxide. Acid 221 was then coupled
with commercial vinylcyclopropylamine fragment 222 using
o-(7-azabenzotriazol-1-yl)-N,N,N0 ,N0-tetramethyluronium hexafluorophosphate
(HATU) and DIPEA to afford peptide 223 following
Boc deprotection. The product could be crystallized upon neutralizing
with NaOH. Amine 223 was subsequently coupled with acid
224 using EDC and N-hydroxy-5-norbornene-2,3-di-carboximide
(HONB) in the presence of N,N-dimethylethylene diamine to afford
linear tripeptide 225. Acid 224 was formed from Boc-
(2S)-amino-non-8-eic acid (229) and 5-methyl-2-pyrazine carboxylic
acid (230) via Boc deprotection and peptide coupling, using
N,N0-disuccinimidyl carbonate and 4-dimethylaminopyridine
(DMAP) to pre-activate acid 230.
Linear trieptide 225 was Boc protected and then subjected to
ring closing metathesis using Zhan-B catalyst (226) in toluene,
using imidazole to quench the catalyst after the reaction. On
kilo-scale, a closely-related ring closing metathesis reaction provided
the desired Z isomer in 61% yield.211 Removal of the Boc carbamate
then provided macrocyclic intermediate 227. Ester
hydrolysis with lithium hydroxide followed by acidification gave
acid 228 which was coupled with cyclopropylsulfonamide (33)
using CDI and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). The isolated
product was dissolved in i-PrOAc and diluted with ethanol.
Water was added portion-wise and the solid isolated by filtration
to afford crystalline paritaprevir hydrate (XXVII).
ABT450 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | +86-18600796368 +86-18600796368 | sales@sjar-tech.com | China | 484 | 58 |
| Nanjing Finetech Chemical Co., Ltd. | 025-85710122 17714198479 | sales@fine-chemtech.com | CHINA | 885 | 55 |
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 32965 | 60 |
| career henan chemical co | +86-0371-86658258 +8613203830695 | sales@coreychem.com | China | 29871 | 58 |
| Hangzhou Cyanochem Co., Ltd. | +86 17788583750 | sales@cyanochem.com | CHINA | 281 | 58 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19553 | 58 |
| Beijing Yibai Biotechnology Co., Ltd | 0086-182-6772-3597 | sales04@yibaibiotech.com | CHINA | 419 | 58 |
| Chongqing Chemdad Co., Ltd | +86-023-6139-8061 +86-86-13650506873 | sales@chemdad.com | China | 39894 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | marketing@targetmol.com | United States | 32161 | 58 |
| HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 | sales@hzclap.com | CHINA | 6312 | 58 |
View Lastest Price from ABT450 manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2025-01-13 | Paritaprevir
1216941-48-8
|
US $0.00 / g | 1g | More Than 99% | 50kg/Month | BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | |
 |
2019-07-06 | ABT450
1216941-48-8
|
US $1.00 / KG | 1G | 98% | 100KG | Career Henan Chemical Co |
-
- Paritaprevir
1216941-48-8
- US $0.00 / g
- More Than 99%
- BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
-
- ABT450
1216941-48-8
- US $1.00 / KG
- 98%
- Career Henan Chemical Co